Also known as: Wolverine Stack, BPC-157 / TB-500 Combo, Healing Stack, BPC + TB
Half-life: BPC-157 ~4 h; TB-500 ~6-8 h
Last reviewed: · Published:
The Wolverine Blend is a research formulation that combines BPC-157 (a gastric pentadecapeptide with broad tissue-protective activity) with TB-500 (the active fragment of Thymosin Beta-4). The nickname comes from the X-Men character's near-instant healing, and the pairing is one of the most widely used recovery stacks in the peptide community. Each compound targets a different stage of the wound-healing cascade: BPC-157 promotes angiogenesis and modulates nitric oxide signalling, while TB-500 drives cell migration through actin upregulation, helping new tissue populate the injury site.
Practitioners use this combination during recovery from soft-tissue injuries — tendinopathies, ligament strains, post-surgical repair, and stubborn overuse injuries that have stalled on conventional rehab alone. Because the two peptides work via complementary rather than redundant mechanisms, anecdotal reports often describe a synergistic effect compared with running either compound alone. There are, however, no published clinical trials of the blend itself — the evidence base comes from individual studies of BPC-157 and TB-500.
Both components are unapproved research chemicals in every major jurisdiction and are banned by WADA. The blend is sold as a single 3 mL lyophilised vial containing 10 mg of each peptide, intended to be reconstituted together so the user can dose both simultaneously.
BPC-157 was first characterised by Predrag Sikiric's group at the University of Zagreb in the early 1990s, derived from a gastric protective protein. TB-500 was developed as a synthetic fragment of Thymosin Beta-4, which was originally isolated from the thymus gland by Allan Goldstein's research group at George Washington University in the 1970s. Both peptides moved from academic research into the human-performance underground in the 2010s, where users discovered empirically that pairing them produced more pronounced soft-tissue recovery than either alone.
The "Wolverine" nickname appeared on peptide-research forums circa 2018-2020 as the pairing became a staple of athlete recovery protocols. UK research-chemical suppliers began offering co-packaged "BPC + TB" kits shortly after to simplify dosing — typically a single vial containing both peptides ready for one-step reconstitution.
Each component is generally well tolerated in the available preclinical and limited clinical evidence. Side effects from the blend are typically the union of those reported for BPC-157 and TB-500 individually — most commonly mild injection-site reactions and transient lightheadedness. No serious adverse events have been consistently reported in published component studies, but no human safety data exists for the combined blend at clinical-trial standard.
Dose Range
250-500 mcg BPC + 2-5 mg TB-500
Frequency
BPC daily, TB-500 twice weekly
Duration
4-6 weeks
Dose Range
250 mcg BPC + 2 mg TB-500
Frequency
BPC daily, TB-500 weekly
Duration
6-8 weeks
Dose Range
250 mcg BPC + 2 mg TB-500
Frequency
BPC 3-4x weekly, TB-500 fortnightly
Duration
4 weeks
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
20 mg
Water Type
Bacteriostatic water (BAC water)
Mixing Volume
3 mL
Half-Life
BPC-157 ~4 h; TB-500 ~6-8 h
Molecular Weight
Blend (BPC-157 1419.5 Da + TB-500 ~889 Da fragment)
Co-packaged vials are typically reconstituted with 3 mL BAC water, giving roughly 333 mcg BPC-157 and 333 mcg TB-500 per 0.1 mL. Store reconstituted vial refrigerated at 2-8°C and use within 28 days. Some practitioners prefer to reconstitute each peptide separately if dosed on different schedules.
Disclosure: PinnyPeptide may earn a commission on purchases made through the links above, at no extra cost to you. We only list vendors we're willing to point our community at, but inclusion is not a clinical endorsement. Always verify each vendor's third-party testing and your local legal status before purchasing.
FDA Status
Neither component is FDA approved for human use. FDA issued a warning letter in 2024 regarding compounded BPC-157 products.
Legal Status
Both components are unregulated research chemicals. Prohibited by WADA and most equine racing authorities.
USA
Not approvedFDA warning letter 2024 regarding BPC-157; neither component approved
EU
Not approvedNot authorized as medicinal products
UK
Not approvedBoth classified as research chemicals
Australia
Not approvedTB-500 banned in horse racing; BPC-157 not evaluated
Russia
Not approvedAvailable as research compounds
Canada
Not approvedHealth Canada has not authorized either
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH
Molecules (2014)
Component study: BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, providing a mechanistic basis for its tendon-healing effects.
View Study →Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D
Nature (2004)
Component study: landmark paper demonstrating that Thymosin Beta-4 promotes cell migration and survival, the mechanism underlying TB-500's tissue-repair activity.
View Study →Gwyer D, Wragg NM, Wilson SL
Cell and Tissue Research (2019)
Component review: covers BPC-157 mechanisms in soft-tissue healing — angiogenesis, inflammation modulation, and growth-factor interactions.
View Study →Gastric pentadecapeptide with broad tissue-healing properties.
Synthetic fragment of Thymosin Beta-4 with potent tissue repair activity.
Wolverine's healing duo plus GHK-Cu — soft-tissue recovery with a cosmetic kicker for skin, hair, and scars.
Four-peptide stack pairing the Glow components with KPV — anti-inflammatory, gut-supportive, and skin-regenerative in one vial.
Track Wolverine Blend (BPC-157 + TB-500) and more with PinnyPeptide.
Sign Up to Track Wolverine Blend (BPC-157 + TB-500)Free forever · defaults pre-filled from this article